Trials / Completed
CompletedNCT02665377
Prevention of Akute Kidney Injury, Hearttransplant, ANP
Prevention of Akute Kidney Injury With Human Atrial Natriuretic Peptide in Patients Undergoing Heart Transplant.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Sahlgrenska University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, blinded, placebo-controlled trial. Patients: Adult patients (\>18 years of age) undergoing de novo Htx, with a preoperative GFR \> 30ml/min, not receiving an ABO-incompatible organ with an ischemia time of \> 6 hours. A donor age \> 70 years is an exclusion criteria. Intervention: Infusion of h-ANP fore five days, starting at the induction of anesthesia. Outcome: Kidney function, evaluated with serum creatinine day 1-7 and kidney clearance, 4-5 Days after Htx plus after 3 and 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ANP | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-09-25
- Primary completion
- 2022-01-08
- Completion
- 2022-01-08
- First posted
- 2016-01-27
- Last updated
- 2022-02-09
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT02665377. Inclusion in this directory is not an endorsement.